FDA Alumni Association Luncheon Brings CBER Priorities Into Focus

October 7, 2026

Karim Mikhail discussed the need for new regulatory approaches, stronger inspection capabilities, and greater public access to the FDA’s scientific reasoning during an FDA Alumni Association luncheon.

The FDA’s Center for Biologics Evaluation and Research (CBER) is examining how it regulates rare disease therapies, oversees manufacturing quality, and communicates regulatory decisions, according to Director Karim Mikhail.

Speaking at an October 7 FDA Alumni Association luncheon in Silver Spring, Maryland, Mikhail identified three priorities: modernizing regulatory frameworks, strengthening FDA leadership, and improving transparency. He urged the agency to reconsider longstanding requirements that may no longer reflect advances in medical science and technology. Tagline Strategies’ Sandy Dean, a former FDA media relations director, attended the event.

For Tagline’s clients and others navigating FDA regulation, three issues stood out from Mikhail’s remarks: how the agency approaches rare disease therapies, the challenges facing its inspection program, and the need for greater transparency in regulatory decision-making.

Different Requirements for Rare Diseases

Mikhail called for significant changes to the regulatory framework for rare and ultra-rare diseases, particularly as individualized therapies become more common.

He questioned the application of requirements developed for large patient populations to treatments intended for only a few dozen patients. Clinical trials involving 12 participants, for example, require different statistical approaches than studies involving thousands. The same distinction, he argued, should be reflected in FDA’s chemistry, manufacturing, and controls (CMC) requirements.

Mikhail said FDA needs clearer regulatory standards that distinguish rare diseases from ultra-rare conditions. He favors establishing consistent principles rather than making exceptions to existing requirements on a case-by-case basis.

He also identified individualized therapies, including treatments developed for specific genetic variants, as an area requiring regulatory changes. FDA must determine how to evaluate these treatments when each product may be developed for a very small number of patients.

Inspections and Transparency

In response to a question, Mikhail acknowledged staffing losses, training needs, and gaps in inspectors’ expertise. He said improving inspection capabilities will take time. Mikhail also called for greater public access to the scientific reasoning behind FDA decisions, while acknowledging legal and confidentiality limits on what the agency can share.

Mikhail did not identify specific changes under consideration or a timeline for issuing new requirements.

Back to All News
Members of the FDA Alumni Association met with the FDA’s Center for Biologics Evaluation and Research Director Karim Mikhail (center) at a luncheon Oct. 7.

Stay in the Know with
Our Latest Insights

Sign up for Tagline’s Newsletter, a digest of regulatory, policy, and communications developments shaping the industries we serve. We promise not to spam you! Our aim is to publish a quarterly newsletter with special features once in a while.

Sign Up